Gut Disease in Systemic Sclerosis—New Approaches to Common Problems
Purpose of review
The goal of this manuscript is to discuss the new diagnostic and potential treatment options for gut disease in systemic sclerosis (SSc). The concepts of quantification of gut perfusion and motility are reviewed. The risks of empiric therapeutics and challenges of studying the microbiome in SSc are discussed.
There are diagnostics that can provide information on gut perfusion and function that are of value in SSc. Easily implemented diagnostic tests are critical to avoid complications of empiric therapy. The role of the microbiome and drugs that target dysmotility are areas of active research.
SSc-related gastrointestinal tract involvement can be heterogeneous in clinical presentation and disease course. Noninvasive gastrointestinal measurement techniques that quantify neural communications with microvasculature in SSc can potentially guide the proper addition and discontinuation of therapeutics. The role of the microbiome and the role of nitric oxide on gut function are important areas of research for understanding gut dysfunction in SSc.
KeywordsSystemic sclerosis Scleroderma Gastrointestinal tract dysmotility Microbiome Ischemia-reperfusion
The authors would like to recognize the University of Utah CCTS/PPH Translational Science Grant, which funded Dr. Bryan Jones and Dr. Erinn Downs-Kelly who performed the CMP analyses described in this article.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Poudel DR, Jayakumar D, Danve A, Sehra ST, Derk CT. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int. 2018;38(10):1847–58. The review discusses the newer focus of gastrointestinal tract disease on mortality in the international systemic sclerosis research community.CrossRefGoogle Scholar
- 3.Poudel DR, Derk CT. Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol. 2018;30(6):588–93.Google Scholar
- 5.Bae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):57–63.Google Scholar
- 12.• Machin DR, Gates PE, Vink H, Frech TM, Donato AJ. Automated measurement of microvascular function reveals dysfunction in systemic sclerosis: a cross-sectional study. J Rheumatol. 2017;44(11):1603–1611. This study introduces the use of sublingual vascular measurement and glycocalyx in systemic sclerosis. J Rheumatol.Google Scholar
- 13.Nussbaum C. Cavalcanti Fernandes Heringa A, Mormanova Z, Puchwein-Schwepcke AF, Bechtold-Dalla Pozza S, Genzel-Boroviczeny O. Early microvascular changes with loss of the glycocalyx in children with type 1 diabetes. J Pediatr. 2014;164(3):584–9 e1.Google Scholar
- 19.Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Tucker J, Marc RE. Retinal remodeling and metabolic alterations in human AMD. Front Cell Neurosci. 2016;10:103.Google Scholar
- 23.Sarosiek I, Selover KH, Katz LA, Semler JR, Wilding GE, Lackner JM, et al. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther. 2010;31(2):313–22.Google Scholar
- 24.•• Malagelada C, Karunaratne TB, Accarino A, Cogliandro RF, Landolfi S, Gori A, et al. Comparison between small bowel manometric patterns and full-thickness biopsy histopathology in severe intestinal dysmotility. Neurogastroenterol Motil. 2018;30(3). https://doi.org/10.1111/nmo.13219. This article highlights the value of combining study techniques to understand pathophysiology of dysmotility.
- 25.Camilleri M, Bharucha AE, di Lorenzo C, Hasler WL, Prather CM, Rao SS, et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil. 2008;20(12):1269–82.CrossRefGoogle Scholar
- 27.Volkmann ER. Intestinal microbiome in scleroderma: recent progress. Curr Opin Rheumatol. 2017;29(6):553–60.Google Scholar
- 29.•• Koch CD, Gladwin MT, Freeman BA, Lundberg JO, Weitzberg E, Morris A. Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radic Biol Med. 2017;105:48–67. This article discusses the interaction between the microbiome and vascular health with a focus on the role of nitric oxide.CrossRefGoogle Scholar
- 32.Clifton HL, Machin DR, Groot HJ, Frech TM, Donato AJ, Richardson RS, et al. Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement. Exp Physiol. 2018;103(10):1412–1424.Google Scholar
- 35.Nakaji G, Fujihara M, Fukata M, Yasuda S, Odashiro K, Maruyama T, et al. Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey. Int J Clin Pharmacol Ther. 2011;49(9):555–62.Google Scholar
- 39.•• Valentin N, Acosta A, Camilleri M. Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to phase II trials. Expert Opin Investig Drugs. 2015;24(6):769–79. This is a comprehensive review of gastrointestinal tract dysmotlity therapeutics and the rationale for their use.CrossRefGoogle Scholar